Astrazeneca's Drug Pipeline Looks Full Despite Wainua Setback

Dow Jones07-13 20:58

1258 GMT - AstraZeneca's drug pipeline is full and diversified, and the market reaction to the failure of its Wainua drug in a late-stage trial for a heart condition looks overdone, Berenberg analysts say in a research note. The U.K. drugmaker is on track for its 2030 revenue target and low expectations on upcoming trial results skew the risk-reward profile to the upside, the analysts say. Berenberg cuts its price target on AstraZeneca to 160 pounds from 170 pounds, citing the Wainua setback and a reduced premium on its research-and-development operations, but says the stock offers top-tier growth at an attractive valuation. Shares fall 1.3% to 126.68 pounds. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 13, 2026 08:58 ET (12:58 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651143131?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 20:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651143131","market":"hk","top_or_hot":-1,"title":"Astrazeneca's Drug Pipeline Looks Full Despite Wainua Setback","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1258 GMT - AstraZeneca's drug pipeline is full and diversified, and the market reaction to the failure of its Wainua drug in a late-stage trial for a heart condition looks overdone, Berenberg analysts say in a research note. The U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker is on track for its 2030 revenue target and low expectations on upcoming trial results skew the risk-reward profile to the upside, the analysts say. Berenberg cuts its price target on AstraZeneca to 160 pounds from 170 pounds, citing the Wainua setback and a reduced premium on its research-and-development operations, but says the stock offers top-tier growth at an attractive valuation. Shares fall 1.3% to 126.68 pounds. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 13, 2026 08:58 ET (12:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astrazeneca's Drug Pipeline Looks Full Despite Wainua Setback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstrazeneca's Drug Pipeline Looks Full Despite Wainua Setback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-13 20:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1258 GMT - AstraZeneca's drug pipeline is full and diversified, and the market reaction to the failure of its Wainua drug in a late-stage trial for a heart condition looks overdone, Berenberg analysts say in a research note. The U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker is on track for its 2030 revenue target and low expectations on upcoming trial results skew the risk-reward profile to the upside, the analysts say. Berenberg cuts its price target on AstraZeneca to 160 pounds from 170 pounds, citing the Wainua setback and a reduced premium on its research-and-development operations, but says the stock offers top-tier growth at an attractive valuation. Shares fall 1.3% to 126.68 pounds. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 13, 2026 08:58 ET (12:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B3T34201.USD","symbol_name":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2651143131","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651143131","pubTimestamp":1783947480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1258 GMT - AstraZeneca's drug pipeline is full and diversified, and the market reaction to the failure of its Wainua drug in a late-stage trial for a heart condition looks overdone, Berenberg analysts say in a research note. The U.K. drugmaker is on track for its 2030 revenue target and low expectations on upcoming trial results skew the risk-reward profile to the upside, the analysts say. Berenberg cuts its price target on AstraZeneca to 160 pounds from 170 pounds, citing the Wainua setback and a reduced premium on its research-and-development operations, but says the stock offers top-tier growth at an attractive valuation. Shares fall 1.3% to 126.68 pounds.  Dow Jones NewswiresJuly 13, 2026 08:58 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4007":"制药","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","AZN":"阿斯利康","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","BK4568":"美国抗疫概念","BK4588":"碎股","AZNH":"ASTRAZENECA PLC ADRhedged","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC"},"translate_title":"尽管 Wainua 遭遇挫折，阿斯利康的药物管道看起来已经满了","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZNH":0.6,"AZN":0.9},"content_text":"1258 GMT - AstraZeneca's drug pipeline is full and diversified, and the market reaction to the failure of its Wainua drug in a late-stage trial for a heart condition looks overdone, Berenberg analysts say in a research note. The U.K. drugmaker is on track for its 2030 revenue target and low expectations on upcoming trial results skew the risk-reward profile to the upside, the analysts say. Berenberg cuts its price target on AstraZeneca to 160 pounds from 170 pounds, citing the Wainua setback and a reduced premium on its research-and-development operations, but says the stock offers top-tier growth at an attractive valuation. Shares fall 1.3% to 126.68 pounds. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 13, 2026 08:58 ET (12:58 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651143131","isCrawlerRequest":true}